A four-color FC analysis was performed on
FC500 analyzer (Beckman Coulter) to characterize MSCs and S-MSCs at day 28: FITC-conjugated CD105 (endoglin), CD31 (PECAM1) antibodies and PE-conjugated CD90 (Thy-1),
CD140a (Platelet-derived growth factor receptor alpha, PDGF RA), CD140b (Platelet-derived growth factor receptor beta, PDGF RB), CD144 (Ve-Cadherin, CDH5), VEGF R1 (Vascular endothelial growth factor receptor 1, FLT1) antibodies and PE-Cy5-conjugated
HLA-DR (human leukocyte antigen-D related), CD34, CD45,
CD11b (integrin alpha M),
CD146 (Melanoma adhesion molecule, MCAM),
CD184 (CXCR4),
CD106 (VCAM1) antibodies and PE-Cy7 conjugated CD73 (5′ nucleotidase) and VEGF R2 (KDR, CD309) antibodies. Mouse anti-Human CD105, CD90, CD73,
HLA-DR,
CD140a, CD31,
CD184,
CD106 were obtained from BD Biosciences (Le Pont de Claix, France), CD34, CD45,
CD11b,
CD146, VEGFR2 from Beckman Coulter,
CD140a,
VEGFR1 from R&D Systems Inc (Minneapolis, USA) and CD144 from Santa-Cruz Biotechnology inc SCBT (Dallas, USA). The isotype-matched mouse IgG1-FITC, IgG1-PE, IgG1-PCy5 and IgG1-PCy7 were used as negative controls. Acquisition and processing data from 7,000 events were analysed using Kaluza software.
Al-Rifai R., Nguyen P., Bouland N., Terryn C., Kanagaratnam L., Poitevin G., François C., Boisson-Vidal C., Sevestre M.A, & Tournois C. (2019). In vivo efficacy of endothelial growth medium stimulated mesenchymal stem cells derived from patients with critical limb ischemia. Journal of Translational Medicine, 17, 261.